Welcome : Guest

FIBROMYALGIA THERAPEUTICS - A GLOBAL MARKET REPORT   

Research Abstract

This report analyzes the Global market for Fibromyalgia Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these market. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 22 companies including many key and niche players such as -

Allergan plc
Boehringer Ingelheim GmbH
Daiichi Sankyo Company Limited
Eli Lilly and Company
Innovative Med Concepts, Inc.

Click here to request a full list of companies covered in the report...

Code: MCP-6917
Price: $4500
Companies: 22
Pages: 78
Date: April 2017
Market Data Tables: 8
 



TABLE OF CONTENTS


  FIBROMYALGIA THERAPEUTICS (Complete Report) Pages : 78   | $4500

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Fibromyalgia Syndrome: A Prelude.....II-1
Table 1: Prevalence Rate (%) of Fibromyalgia Condition in Select Countries (includes corresponding Graph/Chart).....II-1
1$350
   Table 2: Prevalence Rate (%) of Fibromyalgia among Women by Age Group (includes corresponding Graph/Chart).....II-2
Fibromyalgia Therapeutics Market: A Nascent Sector.....II-2
1$350
   A Glance at the Current & Future Fibromyalgia Therapeutics Portfolio.....II-3
FDA Approved Fibromyalgia Drugs.....II-3
1$100
   IMC-1: A Revolutionary Combination Therapy.....II-41$100
   Daiichi Sankyo’s Mirogabalin Drug Improvises on Lyrica.....II-5
Tonix Pharma Develops Newer Sublingual Formulation of Cyclobenzaprine.....II-5
1$100
   Understanding Heightened Effect of Pain in Women Due to Fibromyalgia.....II-61$100
   Inconsistencies and Loopholes in Current Fibromyalgia Diagnoses.....II-71$100
   Fibromyalgia Treatment through High-Pressure Oxygen Application.....II-81$100
   EU approves New Device to Treat Fibromyalgia and Migraine.....II-91$100
   Medications Used in the Fibromyalgia Treatment.....II-10
Pain Relievers.....II-10
Antidepressants.....II-10
Anti-Seizure Drugs.....II-10
Medication for Improving Sleep.....II-10
Muscle Relaxants.....II-10
1$100
   Antipsychotics.....II-11
A Glance at Available Fibromyalgia Drugs.....II-11
Lyrica (pregabalin).....II-11
Cymbalta (duloxetine HCl).....II-11
1$100
   Savella® (milnacipran HCl).....II-12
Fibromyalgia Products in Pipeline.....II-12
Mirogabalin.....II-12
1$100
   IMC-1.....II-13
SWT06101.....II-13
1$100
   Fibromyalgia: An Introduction.....II-14
History of Fibromyalgia.....II-14
Controversies Surrounding Fibromyalgia.....II-14
1$100
   Pathogenesis of Fibromyalgia.....II-15
Fibromyalgia Symptoms.....II-15
1$100
   Diagnosis of Fibromyalgia.....II-161$100
   Non-Pharmacological Treatment of Fibromyalgia.....II-17
Nutritional Therapy.....II-17
Exercise.....II-17
Cognitive Behavior Therapy.....II-17
Pharmacological Treatment Alternatives for Fibromyalgia.....II-17
1$100
   Antidepressants.....II-18
Tricyclic Antidepressants (TCA).....II-18
Dopamine Agonists.....II-18
Muscle Relaxants.....II-18
Selective Serotonin-Norephinephrine Inhibitors (SNRIs).....II-18
Selective Serotonin Reuptake Inhibitors (SSRIs).....II-18
1$100
   Drug Therapy for Fibromyalgia-Related Fatigue.....II-19
Other Therapeutic Agents for Fibromyalgia Treatment.....II-19
Conclusion.....II-19
1$100
   Cannabis Science Introduces Fibromyalgia Pain Relief Medication.....II-20
Soterix Medical Launches PainX tDCS Treatment in Canada.....II-20
Synovation Medical Group to Conduct Study on NeuroMetrix’s Quell® Wearable Pain
  Relief Technology™.....II-20
FDA Grants Fast Track Designation to Innovative Med Concepts’ IMC-1.....II-20
Soterix Medical’s PainX™ Treatment Receives CE Mark Approval.....II-20
Tonix Pharmaceuticals Begins Phase 3 Trial of TNX-102 SL.....II-20
1$100
   Pfizer’s Lyrica Fails to Meet FDA Requirements in Post-Marketing Study.....II-21
Premier Biomedical to Submit Application to FDA for Fibromyalgia Therapy.....II-21
1$100
   Allergan plc (Ireland).....II-22
Boehringer Ingelheim GmbH (Germany).....II-22
Daiichi Sankyo Company Limited (Japan).....II-22
1$100
   Eli Lilly and Company (USA).....II-23
Innovative Med Concepts, Inc. (USA).....II-23
Pfizer, Inc. (USA).....II-23
1$100
   Pierre Fabre Médicament (France).....II-24
SWITCHBIOTECH LLC (USA).....II-24
Zynerba Pharmaceuticals, Inc. (USA).....II-24
1$100
   Table 3: World Recent Past, Current and Future Analysis for Fibromyalgia Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-251$350
   Table 4: World Historic Review for Fibromyalgia Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-261$350
   Table 5: World 14-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart).....II-271$350
   Table 6: European Recent Past, Current and Future Analysis for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-281$350
   Table 7: European Historic Review for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-291$350
   Table 8: European 14-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart).....II-301$350
  
Total Companies Profiled: 22 (including Divisions/Subsidiaries - 23)

Region/Country Players

The United States 12 Canada 1 Japan 4 Europe 5 France 1 Germany 1 Rest of Europe 3 Asia-Pacific (Excluding Japan) 1
Click here to request a full table of contents and more details on this project.